1. Introduction {#s0005}
===============

In 2012, 951,000 new gastric cancer (GC) cases and 723,000 deaths were estimated worldwide, making it the fifth most common tumor ([@bb0055], [@bb0190]). GC is a complex disease arising from environmental and genetic factors. However in individuals infected with *H. pylori*, defined as a definite gastric carcinogen ([@bb0240]), only a few eventually develop into GC, which suggested that host genetic factors may play a crucial role in the susceptibility of GC ([@bb0170]).

The epigenetics is believed to be important in the development of cancers, which was defined as a stably heritable changes through modifying gene expression without DNA sequence alterations ([@bb0045]). The most common epigenetic phenomenon is DNA methylation that refers to a methyl group is conferred to the 5′ carbon of a cytosine in a CpG dinucleotide. It is catalyzed by a family of DNA methyltransferases (DNMTs) mainly consisting of three activated forms: DNMT1, DNMT3A and DNMT3B. DNMT1 is thought to be a maintenance DNA methyltransferase which principally maintains CpG methylation, involving in embryonic development and somatic cells survival ([@bb0010]) and it is encoded by *DNMT1* gene which locates on chromosome 19p13.2 ([@bb0090]). DNMT3A and DNMT3B are considered as de novo methyltransferases which are required for the establishment of embryonic methylation patterns, mainly occurring during gametogenesis and early development ([@bb0165]) and they are encoded by *DNMT3A* and *DNMT3B* genes locating on chromosome 2p23 and 20q11.2 respectively ([@bb0245]).

There is considerable evidence that a number of abnormal changes in single nucleotide polymorphisms (SNPs) of *DNMTs* (*DNMT1*, *DNMT3A* and *DNMT3B*), which could cause DNA hypo-methylation or hyper-methylation ([@bb0065], [@bb0060], [@bb0070], [@bb0265]), are correlated to tumor occurrence or decrease ([@bb0150], [@bb0035], [@bb0160], [@bb0115], [@bb0175], [@bb0225], [@bb0105]) such as head and neck cancer, and colorectal cancer ([@bb0275], [@bb0040]). However, the associations between *DNMTs* SNPs and GC risk were still conflicting ([@bb0090], [@bb0245]). Therefore, for the first time, the effects of *DNMTs* polymorphisms on the susceptibility to GC were systematically and comprehensively estimated.

2. Materials and Methods {#s0010}
========================

2.1. Search {#s0015}
-----------

We did a literature search of PubMed, MEDLINE, Embase, Sinomed, CNKI, and WanFang databases to identify relevant studies up to June 1, 2016, using the search strategy: (stomach OR gastric) AND (neoplasms OR tumors OR cancers OR carcinomas) AND (DNMT1 OR DNMT3A OR DNMT3B OR DNMTs OR DNA methyltransferases). The languages were limited to English and Chinese. The search strategy for PubMed was listed in [Appendix A](#s0100){ref-type="sec"}.

2.2. Selection Criteria {#s0020}
-----------------------

All studies included in the meta-analysis were accorded with the following inclusion criteria: (a). study focused on the association of *DNMTs* polymorphisms and GC risk; (b). case-control or cohort studies. In addition, exclusion criteria were as follows: (a). reviews or meta-analysis; (b). overlapped articles or studies with overlapping data.

2.3. Data Extraction {#s0025}
--------------------

Two investigators independently extracted the following data: first author, year of publication, province/country of origin, ascertainment of cases, source of controls, genotyping methods, *DNMT* genes, SNPs, number of cases and controls, and value of HWE. To ensure accuracy of the data, inconsistencies were discussed with another reviewer until reach a consensus.

2.4. Quality Assessment {#s0030}
-----------------------

The quality of each study was assessed according to the quality assessment criteria (Table S1) ([@bb0185], [@bb0230]), in which the overall quality scores ranged from 0 to 15. Studies with scores ≥ 9 were regarded as high quality studies; otherwise, studies were considered to have a low quality.

2.5. Data Analysis {#s0035}
------------------

Stata software (version 12.0; Stata Corporation, College Station, TX) was used to perform all analysis. We used four types of genetic models ([@bb0120]): homozygote model (homozygous rare vs. homozygous frequent allele), heterozygote model (heterozygous vs. homozygous frequent allele), dominant model (homozygous rare + heterozygous vs. homozygous frequent allele) and recessive model (homozygous rare vs. heterozygous + homozygous frequent allele). Association between *DNMTs* polymorphisms and the GC risk was evaluated by pooled odds ratios (OR), 95% confidence interval (95% CI) and *P* value of Z test (*P*~*OR*~). If 95%IC across 1 or *P*~*OR*~ \< 0.05, a significant association existed. Then if OR or 95%IC \< 1, the mutant gene was a protective factor; otherwise, it was a risk factor. Heterogeneity was analyzed using the *P* value of Q test (*P*~*het*~) and *I*^2^. If *P*~*het*~ \< 0.1 or *I*^2^ \> 50%, a significant heterogeneity existed. And then a sensitivity analysis and a subgroup analysis were performed. Sensitivity analysis was conducted through omitting one study by turns ([@bb0145]), if the 95%CI markedly deviated from the original interval or the *I*^2^ largely decreased, this study was an originator of heterogeneity.

3. Results {#s0040}
==========

3.1. Literature Search and Study Characteristics {#s0045}
------------------------------------------------

A total of 350 records were identified through database searching. After removing duplicates, 274 records were screened on details of the abstracts. In those 249 publications were excluded because 5 were meta-analysis and the other 244 were not related to *DNMTs* SNPs and GC risk. Then 25 full-text articles were obtained to be assessed, in which 5 articles were excluded because 1 was duplicate publication and 4 did not contain information on *DNMTs* SNPs and GC risk. Ultimately, 20 eligible studies ([@bb0090], [@bb0245], [@bb0235], [@bb0110], [@bb0215], [@bb0025], [@bb0210], [@bb0050], [@bb0130], [@bb0255], [@bb0080], [@bb0250], [@bb0125], [@bb0195], [@bb0005], [@bb0200], [@bb0100], [@bb0095], [@bb0020], [@bb0030])were included in the qualitative synthesis, and 7 of them could not be quantitatively synthesized (3 studies respectively reported a different SNP ([@bb0215], [@bb0210], [@bb0125]), 4 studies were conference abstracts ([@bb0100], [@bb0095], [@bb0020], [@bb0030])), so 13 studies involving 3959 GC cases and 5992 healthy controls were finally included in the meta-analysis ([Fig. 1](#f0005){ref-type="fig"}). Among the 20 studies, 18 studies were for Chinese population (respectively from Jiangsu, Jiangxi, Hebei, Shandong, Jilin and Heilongjiang provinces of China), 1 study was for Iranian population (from Fars and Tork) and another one was for Japanese population (from Hiroshima and Yamaguchi). According to the quality assessment criteria (Table S1), scores of the 13 studies (included in the meta-analysis) were 4--12 and 8 studies were with high quality scores ([@bb0230]). The main characteristics of the 13 studies were listed in [Table 1](#t0005){ref-type="table"}.

3.2. Meta-analysis and Systematic Review {#s0050}
----------------------------------------

The associations between *DNMTs* polymorphisms and gastric carcinogenesis were shown in [Table 2](#t0010){ref-type="table"} and the statistically significant associations (only Chinese population were discovered in significant associations) were represented in [Fig. 2](#f0010){ref-type="fig"}. In terms of *DNMT1* and *DNMT3A*, GC risk increased. For rs16999593, there was an association under heterozygote and dominant models (TC vs. TT: OR 1.36, 95%CI 1.14--1.61; TC/CC vs. TT: OR 1.36, 95%CI 1.15--1.60) but not homozygote and recessive models (CC vs. TT: OR 1.36, 95%CI 0.93--1.99; CC vs. TC/TT: OR 1.22, 95%CI 0.84--1.78). For rs1550117, the increased GC risk was discovered under homozygote, dominant and recessive models (AA vs. GG: OR 2.03, 95%CI 1.38--3.00; GA/AA vs. GG: OR 1.20, 95%CI 1.01--1.42; AA vs. GA/GG: OR 1.96, 95%CI 1.33--2.89) but not heterozygote model (GA vs. GG: OR 1.12, 95%CI 0.93--1.33). Conversely, GC risk decreased in *DNMT3B*. For rs1569686, the association was found under dominant model (GT/GG vs. TT: OR 0.74, 95%CI 0.61--0.90) but not heterozygote, homozygote and recessive models (GT vs. TT: OR 0.88, 95%CI 0.69--1.13; GG vs. TT: OR 0.96, 95%CI 0.46--2.01; GG vs. GT/TT: OR 0.97, 95%CI 0.46--2.02). Except all of the above, for rs2228611, rs8101866, rs13420827 and rs2424913, no significant associations were observed among all of the genetic models. Lastly, for SNPs not able to be quantitatively synthesized, the systematic review presented their associations with GC ([Table 3](#t0015){ref-type="table"}). Three SNPs rs36012910, rs7560488 and rs6087990 ([@bb0215], [@bb0210], [@bb0125]) were reported associated with GC and others not.

3.3. Heterogeneity Analysis (Sensitivity and Subgroup Analysis) {#s0055}
---------------------------------------------------------------

There was obvious heterogeneity in rs1550117 (AA vs. GG *I*^2^ 86.9%, *P*~*het*~ 0.000; GA/AA vs. GG: *I*^2^ 69.0%, *P*~*het*~ 0.040; AA vs. GA/GG: *I*^2^ 85.8%, *P*~*het*~ 0.001) and rs1569686 (GT vs. TT: *I*^2^ 83.7%, *P*~*het*~ 0.002; GT/GG vs. TT: *I*^2^ 80.1%, *P*~*het*~ 0.000). A sensitivity analysis was conducted to explore which study primarily influenced the pooled ORs (Table S2, Fig. S1--S2). For rs1550117, the heterogeneity was mostly caused by a study ([@bb0050]), since when it was removed, 95%IC changed in direction of association (OR 1.06, 95%CI 0.87--1.29) and heterogeneity went to zero (*I*^2^ 0%, *P*~*het*~ 0.73). Likewise, for rs1569686, [@bb0205] was found to be the major originator after excluded (95%IC didn\'t change in direction but heterogeneity went to zero: OR 0.49, 95%CI 0.37--0.65, *I*^2^ 0%, *P*~*het*~ 0.88). We compared characteristics of the two studies to the other\'s. Two factors were screened out to explain the heterogeneity: population areas (Jiangsu province or others) and genotyping methods (PCR-RFLP or others). Then a subgroup analysis was performed ([Fig. 3](#f0015){ref-type="fig"}). Population areas: for Jiangsu population, rs1550117 and rs1569686 were associated with GC (OR 1.77, 95%CI 1.25--2.51; OR 0.48, 95%CI 0.36--0.64), but for others (Jiangxi, Jilin and Heilongjiang provinces) no associations were found (OR 1.06, 95%CI 0.87--1.29; OR 1.15, 95%CI 0.87--1.52). Genotyping methods: by PCR-RFLP, rs1550117 and rs1569686 were detected associated with GC (OR 1.77, 95%CI 1.25--2.51; OR 0.49, 95%CI 0.37--0.65) but by others (TaqMan and MassArray) significant associations were not discovered (OR 1.06, 95%CI 0.87--1.29; OR 1.20, 95%CI 0.90--1.60).

4. Discussion {#s0060}
=============

Of the seven SNPs, two (rs16999593 and rs1550117) and one (rs1569686) were significantly associated with GC risk indicating a range of effects from the increased (*DNMT1* and *DNMT3A*) to the reduced (*DNMT3B*).

4.1. *DNMT1* {#s0065}
------------

Our results proved rs16999593 as a potential biomarker for GC susceptibility which was exactly consistent with the results on other types of cancers, such as breast cancer and prostate cancer ([@bb0180], [@bb0075]). In addition, we did not find rs2228611 associated with GC, but it was recently reported that patients carrying the mutant genotypes significantly lived longer than those bearing the wild, indicating that rs2228611 might be a positive prognostic marker for GC survival ([@bb0085]).

4.2. *DNMT3A* and *DNMT3B* {#s0070}
--------------------------

In terms of rs1550117, our findings opposed a previous meta-analysis and we could attribute this contradiction to differences in using homozygote models ([@bb0140]). For rs1569686, we consider it as a protective factor for gastric carcinogenesis and similar results were discovered in head and neck cancer, lung cancer and colorectal cancer ([@bb0040], [@bb0260], [@bb0220], [@bb0270]). However, another study argued it was associated with poor prognosis in GC cases ([@bb0200]). Maybe it played different roles in pathogenesis and prognosis. Particularly, we found in Jiangsu, a high GC incidence area of China ([@bb0135]), mutant rs1550117 doubled the risk and mutant rs1569686 lowered by a half of it. Also, even though some studies discovered TaqMan was more specific and sensitive than PCR-RFLP to detect polymorphisms or virus ([@bb0155], [@bb0015]), we found PCR-RFLP was so far a best method for risk detection in GC. Regarding rs2424913, we didn\'t find it associated with GC in Chinese. A review reported it could significantly decrease cancers in African but not Asian ([@bb0040]). It was speculated whether rs2424913 enabled African to catch GC rather than other populations. Although some meta-analysis studies demonstrated that rs6087990 might confer protection against overall cancers ([@bb0040], [@bb0260]), but it represented an opposite effect on GC as our systematic review showed ([@bb0125]).

4.3. Strengths and Limitations {#s0075}
------------------------------

Previous meta-analysis studies primarily evaluated associations between a few SNPs and cancers without classification, such as GC ([@bb0275], [@bb0040], [@bb0140], [@bb0260], [@bb0220]). The major strengths of our study was its comprehensive and systematic focus on GC and SNPs from three main types of *DNMTs*, 17 SNPs in total. Also, some mistakes in previous results were corrected in our study ([@bb0140]). At the same time, there were some limitations. Firstly, significant heterogeneities were observed for a few genetic models. Although a sensitivity analysis and a subgroup analysis were performed to clarify sources, we cannot find all potential factors. Second the meta-analysis findings were currently restricted to Chinese population pending results from other populations in future studies.

5. Conclusion {#s0080}
=============

Our meta-analysis suggested that *DNMT1* rs16999593 and *DNMT3A* rs1550117 could contribute to GC and that *DNMT3B* rs1569686 might function as a protective factor against gastric carcinogenesis. By using these significant SNPs as biomarkers, it is feasible to estimate the risk of catching GC and thus formulate timely preventive strategy.
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Supplementary data to this article can be found online at [doi:10.1016/j.ebiom.2016.10.028](http://dx.doi.org/10.1016/j.ebiom.2016.10.028){#ir0005}.

![Flow chart of study selection process.](gr1){#f0005}

![Forest plot of *DNMT1*, *DNMT3A* and *DNMT3B* polymorphisms associated with GC risk.](gr2){#f0010}

![Forest plot of subgroup analysis on *DNMT3A* rs1550117 and *DNMT3B* rs1569686 polymorphisms (dominant model) by population area and genetic methods. Population area (Jiangsu province and other provinces: Jiangxi, Jilin and Heilong Jiang provinces, in China) (A); Genetic methods (PCR-RFLP and other methods: TaqMan and MassArray) (B).](gr3){#f0015}

###### 

Characteristics of 13 studies included in the meta-analysis.

Table 1

  Study                  Province/Country                   Ascertainment of cases   Source of controls   Genotyping methods   Gene       SNPs         Sample size (cases/controls)   HWE (controls)   Score
  ---------------------- ---------------------------------- ------------------------ -------------------- -------------------- ---------- ------------ ------------------------------ ---------------- -------
  [@bb0235]              Shandong/China                     Histological             HB                   Sequencing           *DNMT1*    rs16999593   310/420                        0.469            9
  rs2228611              0.423                                                                                                                                                                         
  [@bb0245]              Jiangxi/China                      Histological             HB                   MassArray            *DNMT1*    rs16999593   242/294                        0.120            9
  rs2228611              0.068                                                                                                                                                                         
  rs8101866              0.747                                                                                                                                                                         
  *DNMT3A*               rs1550117                                                   0.444                                                                                                             
  rs13420827                                                                                                                                                                                           
  [@bb0090], [@bb0095]   Jilin/China                        Histological             HB                   TaqMan               *DNMT1*    rs16999593   447/961                        0.910            9
  rs8101866                                                                                                                                                                                            
  [@bb0110]              Fars/Iran, Tork/Iran               Histological             HB                   PCR-RFLP             *DNMT1*    rs2228611    200/200                        0.187            9
  [@bb0025]              Jilin/China                        Histological             HB                   TaqMan               *DNMT3A*   rs1550117    447/961                        0.658            9
  rs13420827             0.833                                                                                                                                                                         
  [@bb0050]              Jiangsu/China                      Histological             HB/PB                PCR-RFLP             *DNMT3A*   rs1550117    208/346                        0.205            12
  [@bb0130]              Jiangsu/China                      NA                       NA                   PCR-RFLP             *DNMT3B*   rs2424913    308/189                        0.942            6
  rs1569686              313/350                            \> 0.05                                                                                                                                    
  [@bb0200], [@bb0205]   Jilin/China                        Histological             HB                   TaqMan               *DNMT3B*   rs1569686    447/961                        0.001            7
  [@bb0255]              Heilongjiang/China                 NA                       NA                   PCR-RFLP             *DNMT3B*   rs1569686    50/60                          0.389            4
  [@bb0080]              Jiangsu/China                      Histological             HB/PB                PCR-RFLP             *DNMT3B*   rs2424913    259/262                        0.926            12
  rs1569686              0.901                                                                                                                                                                         
  [@bb0250]              Jiangsu/China                      NA                       HB                   PCR-RFLP             *DNMT3B*   rs2424913    156/156                        0.968            6
  rs1569686              0.001                                                                                                                                                                         
  [@bb0195]              Hebei/China                        Histological             HB/PB                PCR-RFLP             *DNMT3B*   rs2424913    212/294                        0.654            12
  [@bb0005]              Hiroshima/Japan, Yamaguchi/Japan   Histological             HB                   PCR-RFLP             *DNMT3B*   rs2424913    152/247                        1.000            6

NA, not available; HB, hospital based; PB, population based; PCR-RFLP, polymorphism chain reaction-restriction fragment length polymorphism; *DNMT genes*, deoxyribonucleic acid methyltransferase genes; SNPs, single nucleotide polymorphisms; HWE, Hardy-Weinberg equilibrium.

###### 

Meta-analysis of association between *DNMTs* SNPs and gastric cancer risk.

Table 2

  SNPs                                            N (cases/controls)   OR (95%CI)             *P*~*OR*~[a](#tf0005){ref-type="table-fn"}   *I*^2^      *P*~*het*~[b](#tf0010){ref-type="table-fn"}
  ----------------------------------------------- -------------------- ---------------------- -------------------------------------------- ----------- ---------------------------------------------
  *DNMT1* rs16999593                                                                                                                                   
  TC vs. TT[c](#tf0015){ref-type="table-fn"}      949/1609             **1.36 (1.14,1.61)**   **0.001**                                    **0.0%**    **0.540**
  CC vs. TT[d](#tf0020){ref-type="table-fn"}      654/1202             1.36 (0.93,1.99)       0.117                                        0.0%        0.743
  TC/CC vs. TT[e](#tf0025){ref-type="table-fn"}   999/1675             **1.36 (1.15,1.60)**   **0.000**                                    **0.0%**    **0.720**
  CC vs. TC/TT[f](#tf0030){ref-type="table-fn"}   999/1675             1.22 (0.84,1.78)       0.303                                        0.0%        0.635
                                                                                                                                                       
  *DNMT1* rs2228611                                                                                                                                    
  GA vs. GG[c](#tf0015){ref-type="table-fn"}      656/804              1.09 (0.88,1.36)       0.408                                        0.0%        0.732
  AA vs. GG[d](#tf0020){ref-type="table-fn"}      427/537              0.87 (0.60,1.27)       0.478                                        11.0%       0.325
  GA/AA vs. GG[e](#tf0025){ref-type="table-fn"}   752/912              1.05 (0.86,1.29)       0.622                                        0.0%        0.987
  AA vs. GA/GG[f](#tf0030){ref-type="table-fn"}   752/912              0.97 (0.71,1.32)       0.829                                        56.9%       0.098
                                                                                                                                                       
  *DNMT1* rs8101866                                                                                                                                    
  TC vs. TT[c](#tf0015){ref-type="table-fn"}      643/1159             0.99 (0.81, 1.21)      0.926                                        48.2%       0.165
  CC vs. TT[d](#tf0020){ref-type="table-fn"}      411/751              0.80 (0.55,1.17)       0.252                                        0.0%        0.452
  TC/CC vs. TT[e](#tf0025){ref-type="table-fn"}   686/1255             0.96 (0.80, 1.16)      0.662                                        0.0%        0.324
  CC vs. TC/TT[f](#tf0030){ref-type="table-fn"}   686/1255             0.80 (0.55,1.17)       0.252                                        13.1%       0.283
                                                                                                                                                       
  *DNMT3A* rs1550117                                                                                                                                   
  GA vs. GG[c](#tf0015){ref-type="table-fn"}      839/1548             1.12 (0.93,1.33)       0.229                                        0.0%        0.436
  AA vs. GG[d](#tf0020){ref-type="table-fn"}      605/1102             **2.03 (1.38,3.00)**   **0.000**                                    **86.9%**   **0.000**
  GA/AA vs. GG[e](#tf0025){ref-type="table-fn"}   1104/1892            **1.20 (1.01,1.42)**   **0.038**                                    **69.0%**   **0.040**
  AA vs. GA/GG[f](#tf0030){ref-type="table-fn"}   896/1601             **1.96 (1.33,2.89)**   **0.001**                                    **85.8%**   **0.001**
                                                                                                                                                       
  *DNMT3A* rs13420827                                                                                                                                  
  CG vs. CC[c](#tf0015){ref-type="table-fn"}      656/1206             0.84 (0.68,1.03)       0.090                                        44.3%       0.180
  GG vs. CC[d](#tf0020){ref-type="table-fn"}      495/851              1.16 (0.73,1.85)       0.523                                        0.0%        0.423
  CG/GG vs. CC[e](#tf0025){ref-type="table-fn"}   689/1255             0.87 (0.72,1.06)       0.171                                        0.0%        0.336
  GG vs. CG/CC[f](#tf0030){ref-type="table-fn"}   689/1255             1.23 (0.78,1.95)       0.371                                        0.0%        0.320
                                                                                                                                                       
  *DNMT3B* rs2424913                                                                                                                                   
  CT vs. TT[c](#tf0015){ref-type="table-fn"}      1086/1053            0.66 (0.32,1.36)       0.258                                        0.0%        0.992
  CC vs. TT[d](#tf0020){ref-type="table-fn"}      1075/1032            3.02 (0.12,74.69)      0.500                                        --          --
  CT/CC vs. TT[e](#tf0025){ref-type="table-fn"}   1087/1053            0.71 (0.35,1.44)       0.346                                        0.0%        0.849
  CC vs. CT/TT[f](#tf0030){ref-type="table-fn"}   1087/1053            3.02 (0.12,74.69)      0.500                                        --          --
                                                                                                                                                       
  *DNMT3B* rs1569686                                                                                                                                   
  GT vs. TT[c](#tf0015){ref-type="table-fn"}      745/1262             0.88 (0.69,1.13)       0.320                                        83.7%       0.002
  GG vs. TT[d](#tf0020){ref-type="table-fn"}      644/1072             0.96 (0.46,2.01)       0.923                                        3.1%        0.310
  GT/GG vs. TT[e](#tf0025){ref-type="table-fn"}   1225/1789            **0.74 (0.61,0.90)**   **0.003**                                    **80.1%**   **0.000**
  GG vs. GT/TT[f](#tf0030){ref-type="table-fn"}   756/1283             0.97 (0.46,2.02)       0.930                                        0.0%        0.394

The bolds pointed to models that had statistically significant associations with gastric cancer.

*P* value of the Z-test for odds ration test.

*P* value of the Q-test for heterogeneity test.

Heterozygote model (heterozygous vs. homozygous frequent allele).

Homozygote model (homozygous rare vs. homozygous frequent allele).

Dominant model (homozygous rare + heterozygous vs. homozygous frequent allele).

Recessive model (homozygous rare vs. heterozygous + homozygous frequent allele).

###### 

Systematic review of associations between *DNMTs* SNPs and gastric cancer risk.

Table 3

  Study                  Country   Sample size (cases/controls)   Gene       SNPs                        OR (95%CI)              
  ---------------------- --------- ------------------------------ ---------- --------------------------- ----------------------- -----------------------
  [@bb0245]              China     242/294                        *DNMT1*    rs2114724 C \> T            1.16 (0.81, 1.68)       0.62 (0.30, 1.27)
  [@bb0090], [@bb0095]   China     447/961                        *DNMT1*    rs10420321 A \> G           0.96 (0.66, 1.41)       1.17 (1.88,1.55)
  [@bb0090], [@bb0095]   China     447/961                        *DNMT1*    rs8111085 T \> C            1.08 (0.88, 1.43)       1.18 (0.82, 1.69)
  [@bb0090], [@bb0095]   China     447/961                        *DNMT1*    rs2288349 G \> A            0.93 (0.71, 1.22)       0.81 (0.50, 1.33)
  [@bb0110]              Iran      200/200                        *DNMT1*    rs721186 G \> A             1.12 (0.06, 16.0)       --
  [@bb0110]              Iran      200/200                        *DNMT1*    rs13784 G \> A              --                      --
  [@bb0110]              Iran      200/200                        *DNMT1*    rs11488 A \> T              --                      --
  [@bb0210]              China     340/251                        *DNMT3A*   **rs36012910 A** \> **G**   **2.44 (1.37, 4.33)**   1.00 (0.98, 1.01)
  [@bb0245]              China     242/294                        *DNMT3A*   rs13428812 A \> G           0.93 (0.64, 1.35)       1.11 (0.58, 2.12)
  [@bb0245]              China     242/294                        *DNMT3A*   rs11887120 T \> C           0.96 (0.63, 1.47)       1.26 (0.76, 2.07)
  [@bb0215]              China     405/408                        *DNMT3A*   **rs7560488 T** \> **C**    **1.73 (1.24, 2.41)**   **2.50 (1.01, 6.23)**
  [@bb0200], [@bb0205]   China     447/961                        *DNMT3B*   rs6119954 G \> A            1.00 (0.76, 1.31)       1.37 (0.88, 2.13)
  [@bb0200], [@bb0205]   China     447/961                        *DNMT3B*   rs4911107 A \> G            0.86 (0.26, 2.88)       0.76 (0.23, 2.46)
  [@bb0200], [@bb0205]   China     447/961                        *DNMT3B*   rs4911259 G \> T            0.86 (0.26, 2.89)       0.76 (0.23, 2.45)
  [@bb0200], [@bb0205]   China     447/961                        *DNMT3B*   rs8118663 A \> G            1.28 (0.95, 1.72)       1.32 (0.91, 1.91)
  [@bb0245]              China     242/294                        *DNMT3B*   rs2424908 T \> C            0.98 (0.66, 1.45)       1.05 (0.64, 1.71)
  [@bb0125]              China     313/350                        *DNMT3B*   **rs6087990 C** \> **T**    --                      **1.46 (1.07, 2.01)**

SNPs, single nucleotide polymorphisms; heterozygote model (heterozygous vs. homozygous frequent allele); homozygote model (homozygous rare vs. homozygous frequent allele).

The bolds pointed to SNPs that had statistically significant associations with gastric cancer.

[^1]: These authors contributed equally.
